<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149840">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02132988</url>
  </required_header>
  <id_info>
    <org_study_id>MMH-OPT822-OC001</org_study_id>
    <nct_id>NCT02132988</nct_id>
  </id_info>
  <brief_title>Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer</brief_title>
  <official_title>An Open Labeled Phase II Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mackay Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OBI Pharma, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mackay Memorial Hospital</source>
  <oversight_info>
    <authority>Taiwan : Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of OPT-822/OPT-821 on improving
      Progression-Free Survival (PFS) in subjects who have non-progressive epithelial ovarian,
      fallopian tube, or primary peritoneal cancer after cytoreductive surgery and platinum-based
      chemotherapy as initial treatment for primary disease or as salvage treatment for first
      relapse.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Until disease progression or up to 5 years after the enrollment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Recurrence Rate</measure>
    <time_frame>At 2 years after the enrollment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>OPT-822/OPT-821</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OPT-822/OPT-821</intervention_name>
    <arm_group_label>OPT-822/OPT-821</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects ≥ 21 years of age with histologically confirmed ≥ stage II epithelial
             ovarian, fallopian tube, and primary peritoneal cancer at diagnosis

          -  Who have not progressed after initial treatment with cytoreductive surgery and at
             least 4 cycles of platinum-based chemotherapy.

        OR

          -  Female subjects ≥ 21 years of age with first relapsed epithelial ovarian, fallopian
             tube, and primary peritoneal cancer (regardless of stage at diagnosis)

          -  Who have not progressed after received at least 4 additional cycles of platinum-based
             chemotherapy with or without having undergone secondary cytoreductive surgery .

        Exclusion Criteria:

          -  Subjects with evidence of disease progression according to the GCIG CA125 criteria or
             RECIST 1.1 criteria.

          -  Subjects who are currently receiving any other concomitant anticancer therapy.

          -  Subjects with evidence of extra-abdominal metastasis.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fiona Chen</last_name>
    <phone>886-2-25433535</phone>
    <phone_ext>3941</phone_ext>
    <email>fionaeg0528@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Chen</last_name>
      <phone>886-2-25433535</phone>
      <phone_ext>3941</phone_ext>
      <email>fionaeg0528@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chih-Lung Chang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuh-Cheng Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>May 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
